Expertise in
13
conditions

Dr. Pablo M. Tebas

Infectious Disease
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
35 Years of Experience
Referral may be required
Before you request
Expertise in
13
conditions
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 

Overview

Pablo Tebas is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 35 years.

Dr. Tebas is highly rated in 13 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, Myelitis, and AIDS Dementia Complex.

Dr. Tebas is board certified in Infectious Disease, 2005 and Internal Medicine, 2004. He is actively involved in clinical research, co-authoring 159 peer reviewed articles and participating in 13 clinical trials. Dr. Tebas is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Internal Medicine in PA

Board Certifications

Infectious Disease, 2005
Internal Medicine, 2004

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Pennsylvania Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

MacGregor Infection Medicine and Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Tebas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Methicillin-Resistant Staphylococcus Aureus (MRSA)
Aspergillosis
Monkeypox
Meningitis
Cellulitis
Encephalitis
Pulmonary Tuberculosis
Shingles
Blastomycosis
Flu

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Enrollment Status: Unknown
Publish Date: June 25, 2021
Intervention Type: Drug
Study Drugs: Pegylated Interferon alpha 2b (peg-IFN-?2b), 3BNC117 + 10-1074
Study Phase: Phase 1
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

159 Total Publications

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.
HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.
Journal: Research square
Published: July 10, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Emily A. Blumberg
Infectious Disease
Expertise in
14
conditions
Dr. Emily A. Blumberg
Infectious Disease
Referral may be required
Before you request

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emily Blumberg is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. Blumberg is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Cytomegalovirus Infection, Cytomegalic Inclusion Disease, HIV/AIDS, and Hepatitis C. Dr. Blumberg is board certified in Internal Medicine, 1984. Dr. Blumberg is currently accepting new patients.

Expertise in
7
conditions
Dr. Michael Z. David
Infectious Disease
Expertise in
7
conditions
Dr. Michael Z. David
Infectious Disease
Referral may be required
Before you request

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael David is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. David is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Osteomyelitis, Osteotomy, and Aneurysm Repair. Dr. David is board certified in Internal Medicine, 2004 and Infectious Disease, 2009. Dr. David is currently accepting new patients.

Expertise in
4
conditions
Dr. Karam C. Mounzer
Infectious Disease
Expertise in
4
conditions
Dr. Karam C. Mounzer
Infectious Disease
Referral may be required
Before you request

Penn Infectious Diseases Penn Presbyterian

3801 Filbert Street, Medical Arts Building, Suite 103B, 
Philadelphia, PA 
 (0.8 miles away)
215-662-9908
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Karam Mounzer is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. Mounzer is highly rated in 4 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, AIDS Dysmorphic Syndrome, AIDS Dementia Complex, and Myelitis. Dr. Mounzer is board certified in Infectious Disease, 1997 and Internal Medicine, 1995. Dr. Mounzer is currently accepting new patients.

Frequently Asked Questions about Dr. Pablo M. Tebas

How do I make an appointment with Dr. Pablo M. Tebas?

You can book an appointment with Dr. Pablo M. Tebas by calling their office at 800-789-7366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pablo M. Tebas a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pablo M. Tebas is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pablo M. Tebas specialize in?

While Dr. Pablo M. Tebas is a Infectious Disease, they have specific expertise in HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, and Myelitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Pablo M. Tebas participate in research or clinical trials?

Yes. Dr. Pablo M. Tebas has published 159 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Pablo M. Tebas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pablo M. Tebas accept my insurance?

Dr. Pablo M. Tebas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-789-7366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tebas's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile